drugset / Trial / NCT01400867

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

NCT01400867

Phase 2/3 Completed 163 enrolled Forest Laboratories AstraZeneca · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a study of safety, effectiveness, blood levels and tolerance of Ceftaroline fosamil in children with skin infections receiving antibiotic therapy in the hospital.

Timeline

Start
2011-12
Primary completion
2014-05
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aztreonam Small molecule 30 mg/kg Intravenous
Comparator Cefazolin Small molecule 75 mg/kg Intravenous
Subject Ceftaroline fosamil Other / unclassified 8 mg/kg Intravenous
Subject Ceftaroline fosamil Other / unclassified 12 mg/kg Intravenous
Subject Ceftaroline fosamil Other / unclassified 400 mg Intravenous
Comparator Vancomycin Other / unclassified 15 mg/kg Intravenous
Background CEPHALEXIN ANHYDROUS Small molecule 25 mg/kg Oral
Background Clindamycin Unknown 10 mg/kg Oral
Background Linezolid Other / unclassified 10 mg/kg Oral
Background Linezolid Other / unclassified 600 mg Oral